Investigating how a brain receptor affects sleep therapy for depression

Mechanistic clinical trial evaluating the role of the metabotropic glutamate receptor subtype 5 (mGluR5) in the antidepressant mechanism of Cognitive Behavioral Therapy for Insomnia (CBT-I)

NIH-funded research State University New York Stony Brook · NIH-11128048

This study is looking at how a brain receptor called mGluR5 might affect how well Cognitive Behavioral Therapy for Insomnia (CBT-I) helps adults who have both insomnia and depression, to see if improving sleep can also lift their mood.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionState University New York Stony Brook NIH-funded
Lab location1 site (Stony Brook, United States)
Project IDNIH-11128048 on NIH RePORTER

What this research studies

This research explores the relationship between a specific brain receptor, mGluR5, and the effectiveness of Cognitive Behavioral Therapy for Insomnia (CBT-I) in treating depression. It aims to understand how CBT-I, which focuses on improving sleep, can also alleviate depressive symptoms, particularly in adults who experience insomnia alongside depression. By examining the biological mechanisms involved, the study seeks to uncover how changes in mGluR5 levels may influence treatment outcomes. Patients participating in this research may undergo assessments related to their sleep patterns and depression severity as part of the trial.

Who could benefit from this research

Good fit: Ideal candidates for this research are adults over 21 years old who are experiencing both depression and insomnia.

Not a fit: Patients who do not have symptoms of depression or insomnia may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to improved treatment strategies for depression that incorporate sleep therapy, potentially enhancing recovery rates for patients.

How similar studies have performed: Previous research has shown promising results in understanding the role of mGluR5 in depression and sleep, indicating that this approach has potential based on earlier findings.

Where this research is happening

Stony Brook, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions addictive disorderAlzheimer disease dementiaAlzheimer syndromeAlzheimer's Disease
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.